April 2024 FDA Recall Eylea by Regeneron Pharmaceuticals Inc
D-0479-2024 - Lack of Assurance of Sterility

This Class II drug recall was voluntarily initiated by Regeneron Pharmaceuticals Inc on April 23, 2024 for the product Eylea. The FDA reported the reason for recall as lack of assurance of sterility. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0479-2024

Reason for Recall
Lack of Assurance of Sterility: Complaints of syringe breakage
Initiated
04-23-2024
Reported
05-08-2024
Quantity
251,504 syringes

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Regeneron Pharmaceuticals Inc
EYLEA, (aflibercept) Injection, 2 mg (0.05mL of a 40mg/mL solution), Single-dose Pre-filled Syringe, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, NDC 61755-005-01

Batch or Lot Expiration Information

Lot# 8231500321, Exp 10/31 24; 8231500335, 8231500333, 8231500334, 8231500339, 8231500347, Exp 1/30/25